;PMID: 8630516
;source_file_686.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:45..164] = [t:45..164]
;2)section:[e:168..293] = [t:168..293]
;3)section:[e:297..426] = [t:297..426]
;4)sentence:[e:430..440] = [t:430..440]
;5)sentence:[e:441..567] = [t:441..567]
;6)sentence:[e:568..685] = [t:568..685]
;7)sentence:[e:686..693] = [t:686..693]
;8)sentence:[e:694..942] = [t:694..942]
;9)sentence:[e:943..951] = [t:943..951]
;10)sentence:[e:952..1153] = [t:952..1153]
;11)sentence:[e:1154..1162] = [t:1154..1162]
;12)sentence:[e:1163..1274] = [t:1163..1274]
;13)sentence:[e:1275..1385] = [t:1275..1385]
;14)sentence:[e:1387..1424] = [t:1387..1424]
;15)sentence:[e:1425..1681] = [t:1425..1681]
;16)sentence:[e:1682..1694] = [t:1682..1694]
;17)sentence:[e:1695..2037] = [t:1695..2037]
;18)section:[e:2041..2085] = [t:2041..2085]

;section 0 Span:0..40
;Eur J Endocrinol  1996 Feb;134(2):177-83
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..16] Endocrinol)
        (CD:[18..22] 1996) (IN:[23..31] Feb;134-LRB-) (CD:[31..32] 2)
        (-RRB-:[32..33] -RRB-) (CD:[33..37] :177) (::[37..38] -)
        (CD:[38..40] 83)))

;sentence 1 Span:45..164
;Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation
;in  two out of fifty-six thyroid tumours.
;[62..65]:gene-rna:"p53"
;[85..100]:malignancy:"thyroid tumours"
;[102..105]:gene-rna:"p53"
;[110..113]:gene-rna:"Ras"
;[148..163]:malignancy:"thyroid tumours"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[45..48] Low) (NN:[49..58] frequency))
      (PP (IN:[59..61] of)
        (NP (NN:[62..65] p53) (NNS:[66..75] mutations)))
      (PP-LOC (IN:[76..78] in)
        (NP (JJ:[79..84] human)
           (JJ:[85..92] thyroid) (NNS:[93..100] tumours))))
    (::[100..101] ;)
    (NP
      (NP
        (NP (NN:[102..105] p53)
          (NML-1 (-NONE-:[105..105] *P*)))
        (CC:[106..109] and)
        (NP (NN:[110..113] Ras)
          (NML-1 (NN:[114..122] mutation))))
      (PP-LOC (IN:[123..125] in)
        (NP
          (NP (CD:[127..130] two))
          (PP (IN:[131..134] out)
            (PP (IN:[135..137] of)
              (NP (CD:[138..147] fifty-six)
                 (JJ:[148..155] thyroid) (NNS:[156..163] tumours)))))))
    (.:[163..164] .)))

;section 2 Span:168..293
;Salvatore D, Celetti A, Fabien N, Paulin C, Martelli ML, Battaglia C,
;Califano  D, Monaco C, Viglietto G, Santoro M, Fusco A.
(SEC
  (FRAG (NNP:[168..177] Salvatore) (NNP:[178..179] D) (,:[179..180] ,)
        (NNP:[181..188] Celetti) (NNP:[189..190] A) (,:[190..191] ,)
        (NNP:[192..198] Fabien) (NNP:[199..200] N) (,:[200..201] ,)
        (NNP:[202..208] Paulin) (NNP:[209..210] C) (,:[210..211] ,)
        (NNP:[212..220] Martelli) (NNP:[221..223] ML) (,:[223..224] ,)
        (NNP:[225..234] Battaglia) (NNP:[235..236] C) (,:[236..237] ,)
        (NNP:[238..246] Califano) (NNP:[248..249] D) (,:[249..250] ,)
        (NNP:[251..257] Monaco) (NNP:[258..259] C) (,:[259..260] ,)
        (NNP:[261..270] Viglietto) (NNP:[271..272] G) (,:[272..273] ,)
        (NNP:[274..281] Santoro) (NNP:[282..284] M,) (NNP:[285..290] Fusco)
        (NN:[291..293] A.)))

;section 3 Span:297..426
;Cetro di Endocrinologia ed Oncologia Sperimentale del CNR, Facolta di
;Medicina e  Chirurgia, Universita di Napoli, Naples, Italy.
(SEC
  (FRAG (NNP:[297..302] Cetro) (NNP:[303..305] di)
        (NNP:[306..320] Endocrinologia) (NNP:[321..323] ed)
        (NNP:[324..333] Oncologia) (NNP:[334..346] Sperimentale)
        (FW:[347..350] del) (NNP:[351..354] CNR) (,:[354..355] ,)
        (NNP:[356..363] Facolta) (NNP:[364..366] di) (NNP:[367..375] Medicina)
        (NNP:[376..377] e) (NNP:[379..388] Chirurgia) (,:[388..389] ,)
        (NNP:[390..400] Universita) (NNP:[401..403] di) (NNP:[404..410] Napoli)
        (,:[410..411] ,) (NNP:[412..418] Naples) (,:[418..419] ,)
        (NNP:[420..425] Italy) (.:[425..426] .)))

;sentence 4 Span:430..440
;OBJECTIVE:
(SENT
  (NP (NN:[430..439] OBJECTIVE) (::[439..440] :)))

;sentence 5 Span:441..567
;p53 is a well-known nuclear phosphoprotein encoded by a suppressor  gene know
;to be mutated in various kinds of human tumours.
;[441..444]:gene-protein:"p53"
;[461..483]:gene-protein:"nuclear phosphoprotein"
(SENT
  (S
    (NP-SBJ (NN:[441..444] p53))
    (VP (VBZ:[445..447] is)
      (NP-PRD
        (NP (DT:[448..449] a)
          (ADJP (RB:[450..454] well) (HYPH:[454..455] -) (VBN:[455..460] known))
           (JJ:[461..468] nuclear) (NN:[469..483] phosphoprotein))
        (VP (VBN:[484..491] encoded)
          (NP (-NONE-:[491..491] *))
          (PP (IN:[492..494] by)
            (NP-LGS
              (NP (DT:[495..496] a) (NN:[497..507] suppressor)
                  (NN:[509..513] gene))
              (VP (VB:[514..518] know)
                (S
                  (NP-SBJ (-NONE-:[518..518] *))
                  (VP (TO:[519..521] to)
                    (VP (VB:[522..524] be)
                      (VP (VBN:[525..532] mutated)
                        (PP-LOC (IN:[533..535] in)
                          (NP
                            (NP (JJ:[536..543] various) (NNS:[544..549] kinds))
                            (PP (IN:[550..552] of)
                              (NP (JJ:[553..558] human) (NNS:[559..566] tumours)))))))))))))))
    (.:[566..567] .)))

;sentence 6 Span:568..685
;A relationship  between p53 gene mutation and tumour progression seems to be
;a common feature of  several neoplasias.
;[592..595]:gene-rna:"p53"
;[674..684]:malignancy:"neoplasias"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[568..569] A) (NN:[570..582] relationship))
      (PP (IN:[584..591] between)
        (NP
          (NP (NN:[592..595] p53) (NN:[596..600] gene) (NN:[601..609] mutation))
          (CC:[610..613] and)
          (NP (NN:[614..620] tumour) (NN:[621..632] progression)))))
    (VP (VBZ:[633..638] seems)
      (S
        (NP-SBJ-1 (-NONE-:[638..638] *))
        (VP (TO:[639..641] to)
          (VP (VB:[642..644] be)
            (NP-PRD
              (NP (DT:[645..646] a) (JJ:[647..653] common)
                  (NN:[654..661] feature))
              (PP (IN:[662..664] of)
                (NP (JJ:[666..673] several) (NNS:[674..684] neoplasias))))))))
    (.:[684..685] .)))

;sentence 7 Span:686..693
;DESIGN:
(SENT
  (NP (NN:[686..692] DESIGN) (::[692..693] :)))

;sentence 8 Span:694..942
;In order to investigate the role of p53 mutations in  human thyroid tumours,
;DNA samples derived from fifty-six neoplastic tissues,  ranging from benign
;adenomas to undifferentiated carcinomas, were examined for  the presence of
;p53 gene mutations.
;[730..733]:gene-rna:"p53"
;[754..769]:malignancy:"thyroid tumours"
;[806..824]:malignancy:"neoplastic tissues"
;[840..855]:malignancy:"benign adenomas"
;[859..886]:malignancy:"undifferentiated carcinomas"
;[923..926]:gene-rna:"p53"
(SENT
  (S
    (SBAR (IN:[694..696] In) (NN:[697..702] order)
      (S
        (NP-SBJ (-NONE-:[702..702] *))
        (VP (TO:[703..705] to)
          (VP (VB:[706..717] investigate)
            (NP
              (NP (DT:[718..721] the) (NN:[722..726] role))
              (PP (IN:[727..729] of)
                (NP (NN:[730..733] p53) (NNS:[734..743] mutations)))
              (PP-LOC (IN:[744..746] in)
                (NP (JJ:[748..753] human)
                   (JJ:[754..761] thyroid) (NNS:[762..769] tumours))))))))
    (,:[769..770] ,)
    (NP-SBJ-1
      (NP (NN:[771..774] DNA) (NNS:[775..782] samples))
      (VP (VBN:[783..790] derived)
        (NP (-NONE-:[790..790] *))
        (PP (IN:[791..795] from)
          (NP
            (NP (CD:[796..805] fifty-six)
               (JJ:[806..816] neoplastic) (NNS:[817..824] tissues))
            (,:[824..825] ,)
            (VP (VBG:[827..834] ranging)
              (PP (IN:[835..839] from)
                (NP (JJ:[840..846] benign) (NNS:[847..855] adenomas)))
              (PP (TO:[856..858] to)
                (NP (JJ:[859..875] undifferentiated) (NNS:[876..886] carcinomas))))))))
    (,:[886..887] ,)
    (VP (VBD:[888..892] were)
      (VP (VBN:[893..901] examined)
        (NP-1 (-NONE-:[901..901] *))
        (PP-PRP (IN:[902..905] for)
          (NP
            (NP (DT:[907..910] the) (NN:[911..919] presence))
            (PP (IN:[920..922] of)
              (NP (NN:[923..926] p53) (NN:[927..931] gene)
                  (NNS:[932..941] mutations)))))))
    (.:[941..942] .)))

;sentence 9 Span:943..951
;METHODS:
(SENT
  (NP (NNS:[943..950] METHODS) (::[950..951] :)))

;sentence 10 Span:952..1153
;The analysis has been conducted  using polymerase chain reaction (PCR)
;amplification of the exons 5-9 of the p53  gene followed by single strand
;conformation polymorphism (SSCP) and sequence  analyses.
;[991..1001]:gene-protein:"polymerase"
;[1044..1053]:variation-location:"exons 5-9"
;[1061..1064]:gene-rna:"p53"
(SENT
  (S
    (NP-SBJ-1 (DT:[952..955] The) (NN:[956..964] analysis))
    (VP (VBZ:[965..968] has)
      (VP (VBN:[969..973] been)
        (VP (VBN:[974..983] conducted)
          (NP-1 (-NONE-:[983..983] *))
          (S-MNR
            (NP-SBJ (-NONE-:[983..983] *))
            (VP (VBG:[985..990] using)
              (NP
                (NP
                  (NP
                    (NML
                      (NML (NN:[991..1001] polymerase) (NN:[1002..1007] chain)
                           (NN:[1008..1016] reaction))
                      (NML (-LRB-:[1017..1018] -LRB-) (NN:[1018..1021] PCR)
                           (-RRB-:[1021..1022] -RRB-)))
                    (NN:[1023..1036] amplification))
                  (PP (IN:[1037..1039] of)
                    (NP
                      (NP (DT:[1040..1043] the) (NNS:[1044..1049] exons)
                          (CD:[1050..1051] 5))
                      (PP (HYPH:[1051..1052] -)
                        (NP (CD:[1052..1053] 9)))
                      (PP (IN:[1054..1056] of)
                        (NP (DT:[1057..1060] the) (NN:[1061..1064] p53)
                            (NN:[1066..1070] gene))))))
                (VP (VBN:[1071..1079] followed)
                  (NP (-NONE-:[1079..1079] *))
                  (PP (IN:[1080..1082] by)
                    (NP-LGS
                      (NP
                        (NML
                          (NML
                            (NML (JJ:[1083..1089] single)
                                 (NN:[1090..1096] strand))
                            (NN:[1097..1109] conformation)
                             (NN:[1110..1122] polymorphism))
                          (NML (-LRB-:[1123..1124] -LRB-) (NN:[1124..1128] SSCP)
                               (-RRB-:[1128..1129] -RRB-))))
                      (CC:[1130..1133] and)
                      (NP (NN:[1134..1142] sequence) (NNS:[1144..1152] analyses)))))))))))
    (.:[1152..1153] .)))

;sentence 11 Span:1154..1162
;RESULTS:
(SENT
  (NP (NNS:[1154..1161] RESULTS) (::[1161..1162] :)))

;sentence 12 Span:1163..1274
;One anaplastic carcinoma and one papillary carcinoma showed  p53 gene
;mutations in exons 5 and 8, respectively.
;[1167..1187]:malignancy:"anaplastic carcinoma"
;[1196..1215]:malignancy:"papillary carcinoma"
;[1224..1227]:gene-rna:"p53"
;[1246..1251]...[1252..1253]...[1258..1259]:variation-location:"exons"..."5"..
;."8"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1163..1166] One)
         (JJ:[1167..1177] anaplastic) (NN:[1178..1187] carcinoma))
      (CC:[1188..1191] and)
      (NP (CD:[1192..1195] one)
         (JJ:[1196..1205] papillary) (NN:[1206..1215] carcinoma)))
    (VP (VBD:[1216..1222] showed)
      (NP (NN:[1224..1227] p53) (NN:[1228..1232] gene)
          (NNS:[1233..1242] mutations))
      (PP-LOC (IN:[1243..1245] in)
        (NP
          (NP
            (NML-1 (NNS:[1246..1251] exons))
            (CD:[1252..1253] 5))
          (CC:[1254..1257] and)
          (NP
            (NML-1 (-NONE-:[1257..1257] *P*))
            (CD:[1258..1259] 8))))
      (,:[1259..1260] ,)
      (ADVP (RB:[1261..1273] respectively)))
    (.:[1273..1274] .)))

;sentence 13 Span:1275..1385
;A cell line established from  the papillary carcinoma showed the same
;mutation present in the original tumour.
;[1277..1286]:malignancy:"cell line"
;[1309..1328]:malignancy:"papillary carcinoma"
;[1345..1353]:variation-event:"mutation"
;[1378..1384]:malignancy:"tumour"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1275..1276] A)
         (NN:[1277..1281] cell) (NN:[1282..1286] line))
      (VP (VBN:[1287..1298] established)
        (NP (-NONE-:[1298..1298] *))
        (PP (IN:[1299..1303] from)
          (NP (DT:[1305..1308] the)
             (JJ:[1309..1318] papillary) (NN:[1319..1328] carcinoma)))))
    (VP (VBD:[1329..1335] showed)
      (NP
        (NP (DT:[1336..1339] the) (JJ:[1340..1344] same)
            (NN:[1345..1353] mutation))
        (ADJP (JJ:[1354..1361] present)
          (PP (IN:[1362..1364] in)
            (NP (DT:[1365..1368] the) (JJ:[1369..1377] original)
                (NN:[1378..1384] tumour))))))
    (.:[1384..1385] .)))

;sentence 14 Span:1387..1424
;Both p53 mutations were heterozygous.
;[1392..1395]:gene-rna:"p53"
(SENT
  (S
    (NP-SBJ (DT:[1387..1391] Both) (NN:[1392..1395] p53)
            (NNS:[1396..1405] mutations))
    (VP (VBD:[1406..1410] were)
      (ADJP-PRD (JJ:[1411..1423] heterozygous)))
    (.:[1423..1424] .)))

;sentence 15 Span:1425..1681
;The p53 positive samples were analysed for  other genetic alterations
;frequently detected in human thyroid carcinomas  (mutations of the RET, TRK,
;and ras oncogenes): both p53-mutated samples proved  to be mutated at level
;of codon 13 of the c-Ki-ras gene.
;[1429..1432]:gene-rna:"p53"
;[1524..1542]:malignancy:"thyroid carcinomas"
;[1562..1565]:gene-rna:"RET"
;[1567..1570]:gene-rna:"TRK"
;[1576..1579]:gene-rna:"ras"
;[1597..1600]:gene-rna:"p53"
;[1651..1659]:variation-location:"codon 13"
;[1667..1675]:gene-rna:"c-Ki-ras"
(SENT
  (S
    (S
      (NP-SBJ-1 (DT:[1425..1428] The)
        (ADJP (NN:[1429..1432] p53) (JJ:[1433..1441] positive))
        (NNS:[1442..1449] samples))
      (VP (VBD:[1450..1454] were)
        (VP (VBN:[1455..1463] analysed)
          (NP-1 (-NONE-:[1463..1463] *))
          (PP-PRP (IN:[1464..1467] for)
            (NP
              (NP (JJ:[1469..1474] other) (JJ:[1475..1482] genetic)
                  (NNS:[1483..1494] alterations))
              (VP
                (ADVP (RB:[1495..1505] frequently))
                (VBN:[1506..1514] detected)
                (NP (-NONE-:[1514..1514] *))
                (PP-LOC (IN:[1515..1517] in)
                  (NP (JJ:[1518..1523] human)
                     (JJ:[1524..1531] thyroid) (NNS:[1532..1542] carcinomas)
                    (PRN (-LRB-:[1544..1545] -LRB-)
                      (NP
                        (NP (NNS:[1545..1554] mutations))
                        (PP (IN:[1555..1557] of)
                          (NP (DT:[1558..1561] the)
                            (NML
                              (NML (NN:[1562..1565] RET)
                                (NML-2 (-NONE-:[1565..1565] *P*)))
                              (,:[1565..1566] ,)
                              (NML (NN:[1567..1570] TRK)
                                (NML-2 (-NONE-:[1570..1570] *P*)))
                              (,:[1570..1571] ,) (CC:[1572..1575] and)
                              (NML (NN:[1576..1579] ras)
                                (NML-2 (NNS:[1580..1589] oncogenes)))))))
                      (-RRB-:[1589..1590] -RRB-))))))))))
    (::[1590..1591] :)
    (S
      (NP-SBJ-3 (DT:[1592..1596] both)
        (ADJP (NN:[1597..1600] p53) (HYPH:[1600..1601] -)
              (VBN:[1601..1608] mutated))
        (NNS:[1609..1616] samples))
      (VP (VBD:[1617..1623] proved)
        (S
          (NP-SBJ-3 (-NONE-:[1623..1623] *))
          (VP (TO:[1625..1627] to)
            (VP (VB:[1628..1630] be)
              (VP (VBN:[1631..1638] mutated)
                (NP-3 (-NONE-:[1638..1638] *))
                (PP (IN:[1639..1641] at)
                  (NP
                    (NP (NN:[1642..1647] level))
                    (PP (IN:[1648..1650] of)
                      (NP
                        (NP (NN:[1651..1656] codon) (CD:[1657..1659] 13))
                        (PP (IN:[1660..1662] of)
                          (NP (DT:[1663..1666] the) (NN:[1667..1675] c-Ki-ras)
                              (NN:[1676..1680] gene)))))))))))))
    (.:[1680..1681] .)))

;sentence 16 Span:1682..1694
;CONCLUSIONS:
(SENT
  (NP (NNS:[1682..1693] CONCLUSIONS) (::[1693..1694] :)))

;sentence 17 Span:1695..2037
;Our data  confirm that p53 gene alterations are rare in well-differentiated
;thyroid  tumours, that they are an important requirement for the
;establishment in culture  of human thyroid carcinoma cell lines, and that
;they can be associated with  other genetic alterations, namely ras mutations,
;in the malignant progression of  thyroid tumours.
;[1718..1721]:gene-rna:"p53"
;[1751..1787]:malignancy:"well-differentiated thyroid  tumours"
;[1871..1899]:malignancy:"thyroid carcinoma cell lines"
;[1973..1976]:gene-rna:"ras"
;[2021..2036]:malignancy:"thyroid tumours"
(SENT
  (S
    (NP-SBJ (PRP$:[1695..1698] Our) (NNS:[1699..1703] data))
    (VP (VBP:[1705..1712] confirm)
      (SBAR
        (SBAR (IN:[1713..1717] that)
          (S
            (NP-SBJ (NN:[1718..1721] p53) (NN:[1722..1726] gene)
                    (NNS:[1727..1738] alterations))
            (VP (VBP:[1739..1742] are)
              (ADJP-PRD (JJ:[1743..1747] rare))
              (PP-LOC (IN:[1748..1750] in)
                (NP
                  (ADJP (RB:[1751..1755] well) (HYPH:[1755..1756] -)
                        (VBN:[1756..1770] differentiated))
                  (JJ:[1771..1778] thyroid) (NNS:[1780..1787] tumours))))))
        (,:[1787..1788] ,)
        (SBAR (IN:[1789..1793] that)
          (S
            (NP-SBJ (PRP:[1794..1798] they))
            (VP (VBP:[1799..1802] are)
              (NP-PRD
                (NP (DT:[1803..1805] an) (JJ:[1806..1815] important)
                    (NN:[1816..1827] requirement))
                (PP (IN:[1828..1831] for)
                  (NP
                    (NP (DT:[1832..1835] the) (NN:[1836..1849] establishment))
                    (PP (IN:[1850..1852] in)
                      (NP (NN:[1853..1860] culture)))
                    (PP (IN:[1862..1864] of)
                      (NP
                        (NML (JJ:[1865..1870] human) (JJ:[1871..1878] thyroid))
                        (NN:[1879..1888] carcinoma) (NN:[1889..1893] cell)
                         (NNS:[1894..1899] lines)))))))))
        (,:[1899..1900] ,) (CC:[1901..1904] and)
        (SBAR (IN:[1905..1909] that)
          (S
            (NP-SBJ-1 (PRP:[1910..1914] they))
            (VP (MD:[1915..1918] can)
              (VP (VB:[1919..1921] be)
                (VP (VBN:[1922..1932] associated)
                  (NP-1 (-NONE-:[1932..1932] *))
                  (PP-CLR (IN:[1933..1937] with)
                    (NP
                      (NP (JJ:[1939..1944] other) (JJ:[1945..1952] genetic)
                          (NNS:[1953..1964] alterations))
                      (,:[1964..1965] ,)
                      (NP
                        (ADVP (RB:[1966..1972] namely))
                        (NN:[1973..1976] ras) (NNS:[1977..1986] mutations))))
                  (,:[1986..1987] ,)
                  (PP (IN:[1988..1990] in)
                    (NP
                      (NP (DT:[1991..1994] the) (JJ:[1995..2004] malignant)
                          (NN:[2005..2016] progression))
                      (PP (IN:[2017..2019] of)
                        (NP (JJ:[2021..2028] thyroid) (NNS:[2029..2036] tumours))))))))))))
    (.:[2036..2037] .)))

;section 18 Span:2041..2085
;PMID: 8630516 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2041..2045] PMID) (::[2045..2046] :) (CD:[2047..2054] 8630516)
        (NN:[2055..2056] -LSB-) (NNP:[2056..2062] PubMed) (::[2063..2064] -)
        (NN:[2065..2072] indexed) (IN:[2073..2076] for)
        (NNP:[2077..2085] MEDLINE-RSB-)))
